CMS’ drug price negotiations are advancing, but new indications and exclusivity rules could complicate future pricing cycles. CMS gained the authority to negotiate list prices with drug manufacturers ...
Pharmaceutical manufacturers and distributors will now have to explain to the state of Minnesota why 10 classes of drugs that treat cancer and other disorders are selling well above their listed costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results